Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash from Investing Activities (2018 - 2025)

Serina Therapeutics' Cash from Investing Activities history spans 7 years, with the latest figure at -$13000.0 for Q3 2025.

  • For Q3 2025, Cash from Investing Activities fell 333.33% year-over-year to -$13000.0; the TTM value through Sep 2025 reached -$64000.0, up 26.44%, while the annual FY2024 figure was -$22000.0, 95.63% up from the prior year.
  • Cash from Investing Activities for Q3 2025 was -$13000.0 at Serina Therapeutics, up from -$46000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $9.7 million in Q2 2023 and bottomed at -$10.0 million in Q1 2023.
  • The 4-year median for Cash from Investing Activities is -$13500.0 (2024), against an average of $6750.0.
  • The largest annual shift saw Cash from Investing Activities soared 10500.0% in 2021 before it tumbled 333.33% in 2025.
  • A 4-year view of Cash from Investing Activities shows it stood at -$50000.0 in 2021, then tumbled by 40.0% to -$70000.0 in 2023, then skyrocketed by 92.86% to -$5000.0 in 2024, then plummeted by 160.0% to -$13000.0 in 2025.
  • Per Business Quant, the three most recent readings for SER's Cash from Investing Activities are -$13000.0 (Q3 2025), -$46000.0 (Q2 2025), and -$5000.0 (Q4 2024).